grant
Inhibition of MMP-9 Activity Impairs Working Memory in Zebrafish Through Changes in Overall Hippocampal Excitation
Organization VANDERBILT UNIVERSITY MEDICAL CENTERLocation NASHVILLE, UNITED STATESPosted 15 Sept 2022Deadline 30 Apr 2028
NIHUS FederalResearch GrantFY20252-photon21+ years old65 and older65 or older65 years of age and older65 years of age or more65 years of age or older65+ years65+ years old92-kDa Gelatinase92-kDa Type IV CollagenaseAD dementiaAD related dementiaADRDAcuteAdultAdult HumanAffectAgeAged 65 and OverAgingAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer risk factorAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimer's and related dementiasAlzheimer's dementia and related dementiaAlzheimer's dementia or related dementiaAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorderAlzheimer's disease or related dementiaAlzheimer's disease related dementiaAlzheimer's disease riskAlzheimers DementiaAmentiaAmericanAmmon HornAreaAssayAssociation LearningAssociative LearningBioassayBiological AssayBiological MarkersBlood VesselsBrachydanio rerioBrainBrain Nervous SystemBrain VascularBrain Vascular reactivityCause of DeathCephalicCerebrospinal FluidCerebrovascular CirculationCerebrovascular systemChronicCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive deficitsCognitive function abnormalCornu AmmonisCoupledCranialCuesDanio rerioDataDementiaDiseaseDisorderDisturbance in cognitionEncephalonEndotheliumGelGelatinase BGoalsHeadHigh PrevalenceHippocampusHyperemiaHypertensionImageImmediate MemoryImmunoblottingImmunofluorescenceImmunofluorescence ImmunologicImpaired cognitionImpairmentIn SituInhibition of Matrix MetalloproteinasesInhibition of Matrix Metalloproteinases PathwayInvoluntary MuscleLaser-Doppler FlowmetryLearningLinear RegressionsLinkMMP-9MMP-9 ProteinMacrophage GelatinaseMatrix Metalloproteinase-9MeasuresMemoryMemory DeficitMemory impairmentMiceMice MammalsMolecularMurineMusMuscle functionNerve CellsNerve DegenerationNerve UnitNeural CellNeurocyteNeuron DegenerationNeuronsNeurovascular dysfunctionParticipantPatientsPavlovian conditioningPopulationPopulation DynamicsPrevalencePrimary Senile Degenerative DementiaRegistriesRegulationResearchRoleSB 3CT compoundSB-3CTShort-Term MemorySliceSmooth MuscleSourceTechniquesTestingTimeType V CollagenaseUnited StatesVascular Hypertensive DiseaseVascular Hypertensive DisorderVasodilatationVasodilationVasorelaxationWestern BlottingWestern ImmunoblottingZebra DanioZebra FishZebrafishabove age 65adulthoodafter age 65age 65 and greaterage 65 and olderage 65 or olderageage of 65 years onwardaged 65 and greateraged 65+aged ≥65agesalzheimer riskassociative conditioningawakebio-markersbiologic markerbiomarkerblood flow in brainblood vessels in the brainbrain blood circulationbrain blood flowbrain blood vesselsbrain vasculaturecardiac disease induced cognitive impairmentcerebral blood flowcerebral blood vesselcerebral circulationcerebral spinal fluidcerebral vascularcerebral vascular reactivitycerebral vasculaturecerebro-vascularcerebrocirculationcerebrovascularcerebrovascular blood flowcerebrovascular contribution to cognitive impairment and dementiacerebrovascular reactivitycerebrovascular vesselscerebrovasculatureclassical conditioningcognitive defectscognitive dysfunctioncognitive lossconditioned fearconfocal imagingdisabilitydiscrete timefear conditioninghigh blood pressurehippocampalhuman old age (65+)hyperpiesiahyperpiesishypertensivehypertensive diseasehypertensive disorderimagingin vivoinhibitormalleable riskmemory consolidationmemory dysfunctionmemory recallmodifiable riskmouse modelmurine modelneural degenerationneurodegenerationneurodegenerativeneurological degenerationneuronalneuronal circuitneuronal circuitryneuronal degenerationneurovascular abnormalityneurovascular dysregulationneurovascular impairmentneurovascular pathologyneurovasculopathynew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetover 65 yearspreventpreventingprimary degenerative dementiaprotein blottingsenile dementia of the Alzheimer typesocial rolespinal fluidstatisticstherapeutic targettraining opportunitytwo-photonvascularvascular cognitive impairment and dementiavascular contribution to impairment or dementiavascular contributions to cognition/dementiavascular contributions to cognitive decline and dementiavascular contributions to cognitive impairment and dementiavascular risk factorworking memory≥65 years
Description preview
Alzheimer’s disease (AD) is the most common type of dementia and according to the Alzheimer’s Association, it currently affects approximately 7.2 million Americans age 65 and older. Even more striking, AD prevalence is expected to increase to nearly 13 million Americans by 2050. Unfortunately, despite this high prevalence, the molecular and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click